![]() |
|
|
Vol. 288, Issue 1, 260-269, January 1999
Laboratory of the Biology of Addictive Diseases, The Rockefeller
University, New York, New York
Dynorphin peptides act preferentially at
- as well as µ- and
-opioid receptors. This study was conducted to determine whether dynorphin peptides act to lower dopaminergic tone in the
tuberoinfundibular system, resulting in elevated serum prolactin levels
and, if so, whether such an effect is mediated by the opioid receptors.
Dose-related increases in serum prolactin levels were observed after
dynorphin A1-13 was administered i.v. in doses of 120 and
500 µg/kg to healthy human volunteers with no history of drug or
alcohol abuse. Studies were then conducted to determine whether this
effect is opioid receptor mediated and, if so, whether at
- or µ types. Pretreatment with the opioid antagonist nalmefene (30 mg i.v.), which has high affinity at both µ- and
-opioid receptors, caused a
greater attenuation in dynorphin A1-13-stimulated
increases in serum prolactin levels than pretreatment with similarly
high doses of naloxone, an antagonist with lower affinity for both µ-
and
-opioid receptors. These results suggest dynorphin
A1-13 lowers tuberoinfundibular dopaminergic tone through
action at
- and possibly µ-opioid receptors. Female subjects
were significantly more responsive to the prolactin effects of
dynorphin than were male subjects. Dynorphin gene expression, dynorphin
peptides, and
-opioid receptor gene expression and binding have been
shown to be altered in response to cocaine administration. Also, both dynorphin peptides and synthetic
-opioid agonists have been shown to
lower dopamine levels in the nucleus accumbens and to attenuate cocaine-induced surges in dopamine levels. Thus, a dynorphin-like compound capable of reaching critical mesolimbic-mesocortical and
nigrostriatal dopaminergic systems may be effective in the management
of cocaine addiction.
This article has been cited by other articles:
![]() |
E. R. Butelman, S. Rus, D. S. Simpson, A. Wolf, T. E. Prisinzano, and M. J. Kreek The Effects of Herkinorin, the First {micro}-Selective Ligand from a Salvinorin A-Derived Scaffold, in a Neuroendocrine Biomarker Assay in Nonhuman Primates J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 154 - 160. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Butelman, M. Mandau, K. Tidgewell, T. E. Prisinzano, V. Yuferov, and M. J. Kreek Effects of Salvinorin A, a {kappa}-Opioid Hallucinogen, on a Neuroendocrine Biomarker Assay in Nonhuman Primates with High {kappa}-Receptor Homology to Humans J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 300 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Bart, L. Borg, J. H. Schluger, M. Green, A. Ho, and M. J. Kreek Suppressed Prolactin Response to Dynorphin A1-13 in Methadone-Maintained Versus Control Subjects J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 581 - 587. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ben-Jonathan and R. Hnasko Dopamine as a Prolactin (PRL) Inhibitor Endocr. Rev., December 1, 2001; 22(6): 724 - 763. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Butelman, M. C. H. Ko, J. R. Traynor, J. A. Vivian, M.-J. Kreek, and J. H. Woods GR89,696: A Potent kappa -Opioid Agonist with Subtype Selectivity in Rhesus Monkeys J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1049 - 1059. [Abstract] [Full Text] [PDF] |
||||